Tagged 2014

Redesigned Government Website Helps Taxpayers Tackle 2014 Taxes, Other Tax Issues

WASHINGTON (PRWEB) April 14, 2015

As taxpayers face the worst filing season in more than a decade in terms of IRS customer service, the Taxpayer Advocate Service (TAS), an independent organization within the IRS that helps taxpayers resolve problems, has launched a redesigned website to help people navigate common tax issues and situations on their 2014 returns and beyond.

“It’s vital that all taxpayers have access to clear, concise information to help them understand and address their sometimes complex tax issues,” said National Taxpayer Advocate Nina Olson. “Our redesigned Tax Toolkit enables taxpayers to quickly find the resources they need to understand and take steps to resolve these issues.”

The redesigned site is optimized to enable users seeking help on a range of common tax issues – from finding a refund to navigating an audit – to find information quickly, and from any device. Each issue page provides general information, offers next steps, advises about possible consequences of action or non-action, and suggests further resources. Some common issues – like “I can’t pay my taxes” – also include videos to explain the basics and guide taxpayers through their options.

Each tax issue page also links to elements of the Taxpayer Bill of Rights. Adopted by the IRS in 2014, these 10 rights apply to all taxpayer interactions with the IRS. The site explains what each right means to taxpayers and provides easily digestible examples and related resources.

Additional site enhancements include:


Enhanced User Experience: Developed using responsive web design, the redesigned Tax Toolkit now enables people to more easily find tax information on the go via their smartphones and other mobile devices.
News & Information: As tax law continues to evolve, taxpayers can find timely, reliable information to help them address issues with their tax accounts and prevent future problems. The site also features Congressional testimony, blog posts, and other writings by the National Taxpayer Advocate.
Estimators: TAS developed these tools to give taxpayers more information about how issues directly affect them, particularly issues related to the Affordable Care Act. Current tools include an estimator for the Premium Tax Credit and for Individual Shared Responsibility payments.

To learn more, visit http://www.taxpayeradvocate.irs.gov.

About the Taxpayer Advocate Service

The Taxpayer Advocate Service (TAS) is an independent organization within the Internal Revenue Service (IRS) that helps taxpayers and protects taxpayer rights. You can find your local advocate’s number at http://www.taxpayeradvocate.irs.gov, or call TAS toll-free at 1–877–777–4778. TAS can help if you need assistance resolving an IRS problem, if your problem is causing financial difficulty, or if you believe an IRS system or procedure isn’t working as it should — and our service is free. For more information about TAS and your rights under the Taxpayer Bill of Rights, go to http://www.taxpayeradvocate.irs.gov.







More Credit Offer Press Releases

Road to success: NovaStors extensive revenue growth in 2014 enables new investments for 2015

Agoura Hills, CA (PRWEB) March 26, 2015

Ending the 2014 fiscal year with such a success enables NovaStor, an international provider of award-winning backup solutions, to further invest into the future. Enhancing software features, further improving usability, and expanding the technical support department are just few areas of investment for the 2015 plan. Besides improving the network backup software NovaBACKUP DataCenter, NovaStor also started a new marketing initiative. To keep customers and interested parties up to date on the newest backup trends, NovaStor has added a bi-weekly newsletter and a monthly webinar that talks about network backup and NovaBACKUP DataCenter.

The market for network backup software used in heterogeneous environments from 5 to 500 servers, seems rather unstable at the moment. Symantec recently stopped offering the Backup Exec Appliance, and is now thinking about separating Backup Exec from their other products, CA sold Arcserve to an equity company, and Arkeia is now a part of Western Digital, a storage developer. Discussions about big companies that are re-aligning their focus, are found all over the internet.

“But what happens with the rest of us; companies, governments, universities and public utilities that don’t have the budget to purchase and maintain enterprise solutions that have to run on specific hardware?” asks Mike Andrews, Managing Director at NovaStor. “NovaBACKUP DataCenter’s sweet spot is performing like an enterprise backup software that is able to protect business critical data, but without all the enterprise issues, such as complex pricing models, confusing interfaces, and useless features.”

The revenue growth indicates that there is a need for a stable, reliable and cost effective data protection solution that includes support for the newest technologies and addresses the requirements of small and medium sized IT environments using the hardware of their choice. NovaStor is listening to its customers while keeping a pulse on the changing market trends to continuously improve the network backup solution NovaBACKUP DataCenter.

NovaStor expanded their marketing strategy to capitalize on this growth by adding a monthly webinar and a bi-weekly newsletter with a wide variety of topics around network backup, without the typical sales and marketing pitches. On April 3rd NovaStor’s Director of Products, Nathan Fouarge, is introducing the advantages of multistreaming for backups to disk and tape devices. During this 45 minute webinar, starting at 11AM (PDT), he will highlight ways to shorten backup and restore windows and explain how this feature can save IT budgets. Everybody who is interested is invited to join the webinar and chat with him afterwards.

Register here to attend the Webinar about Multistreaming.

More about NovaBACKUP DataCenter: http://www.novastor.com/DC.

About NovaStor

NovaStor® (http://www.novastor.com/) is an international provider of powerful, affordable, all inclusive data-protection solutions for physical and virtual environments. NovaStor provides backup & restore solutions to small and medium business (SMB) as well as heterogeneous environments to protect data on both sides of the cloud. NovaStor’s SMB solution NovaBACKUP® is rated #1 for businesses requiring local and remote protection of Windows Servers, VMware, Hyper-V and NAS environments with advanced monitoring capability, detailed reporting, and administration from a Central Management Console. NovaStor’s network backup solution NovaBACKUP DataCenter brings F500 references, scalability, reliability and speed to heterogeneous environments; a single pane of glass designed to reduce administrative effort and lower TCO. NovaStor’ Setup Assistance is an industry first where experts relieve clients from the complexity of installation and support. NovaStor is management-owned with over 1,000 partners, and millions of seats distributed. With global headquarters located in Zug, Switzerland and offices in Germany (Hamburg) and the USA (Agoura Hills), NovaStor is also represented in numerous other countries through partnerships.







More Interest Rates Press Releases

Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com

Dallas, Tx (PRWEB) January 20, 2015

The report ” Muscular Dystrophy Pipeline Review, H2 2014″ provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dystrophy-pipeline-review-h2-2014-market-report.html .

It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. Companies discussed in this Muscular Dystrophy Pipeline Review H2 2014 report include Acceleron Pharma, Inc., aTyr Pharma, Inc., Benitec Biopharma Limited, Bioblast Pharma Ltd., Calzada Limited, Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Genethon, Genzyme Corporation, Isis Pharmaceuticals, Inc., Marina Biotech, Inc., Novogen Limited, Prosensa Therapeutics B.V., Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Valentia Biopharma S.L., Zambon Company S.p.A. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=256231 .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Table of Contents

List of Tables

Number of Products under Development for Ischemia, H2 2014 15

Number of Products under Development for Ischemia – Comparative Analysis, H2 2014 16

Number of Products under Development by Companies, H2 2014 18

Number of Products under Development by Companies, H2 2014 (Contd..1) 19

Number of Products under Development by Companies, H2 2014 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2014 22

Comparative Analysis by Late Stage Development, H2 2014 23

Comparative Analysis by Clinical Stage Development, H2 2014 24

Comparative Analysis by Early Stage Development, H2 2014 25

Comparative Analysis by Unknown Stage Development, H2 2014 26

Products under Development by Companies, H2 2014 27

Products under Development by Companies, H2 2014 (Contd..1) 28

Products under Development by Companies, H2 2014 (Contd..2) 29

Products under Development by Companies, H2 2014 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2014 31

Ischemia – Pipeline by Alize Pharma SAS, H2 2014 32

Ischemia – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 33

Ischemia – Pipeline by AnGes MG, Inc., H2 2014 34

Ischemia – Pipeline by Apceth GmbH & Co. KG, H2 2014 35

Ischemia – Pipeline by Athersys, Inc., H2 2014 36

Ischemia – Pipeline by Baxter International Inc., H2 2014 37

Ischemia – Pipeline by Cellmid Limited, H2 2014 38

Ischemia – Pipeline by CoDa Therapeutics, Inc., H2 2014 39

Ischemia – Pipeline by DNAVEC Corporation, H2 2014 40

Ischemia – Pipeline by GlaxoSmithKline plc, H2 2014 41

Ischemia – Pipeline by Hemostemix Ltd, H2 2014 42

Ischemia – Pipeline by Human Stem Cells Institute, H2 2014 43

Ischemia – Pipeline by IntelliCell BioSciences Inc., H2 2014 44

Ischemia – Pipeline by Juventas Therapeutics, Inc., H2 2014 45

Ischemia – Pipeline by Kasiak Research Pvt. Ltd., H2 2014 46

Ischemia – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 47

Ischemia – Pipeline by Mast Therapeutics, Inc., H2 2014 48

List of Figures

Number of Products under Development for Ischemia, H2 2014 15

Number of Products under Development for Ischemia – Comparative Analysis, H2 2014 16

Number of Products under Development by Companies, H2 2014 17

Number of Products under Investigation by Universities/Institutes, H2 2014 21

Comparative Analysis by Clinical Stage Development, H2 2014 24

Comparative Analysis by Early Stage Products, H2 2014 25

Assessment by Monotherapy Products, H2 2014 68

Number of Products by Top 10 Targets, H2 2014 69

Number of Products by Stage and Top 10 Targets, H2 2014 69

Number of Products by Top 10 Mechanism of Actions, H2 2014 71

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 71

Number of Products by Top 10 Routes of Administration, H2 2014 73

Number of Products by Stage and Top 10 Routes of Administration, H2 2014 73

Number of Products by Top 10 Molecule Types, H2 2014 75

Number of Products by Stage and Top 10 Molecule Types, H2 2014 75

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.







More Compare Offers Press Releases